Drug Approval | July 31, 2022
Casper Pharma completed USFDA pre-approval inspection
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Subscribe To Our Newsletter & Stay Updated
